Tesamorelin is a GHRH analog stabilised against DPP-4 cleavage by an N-terminal trans-3-hexenoic acid modification.
Tesamorelin adds a trans-3-hexenoic acid moiety to the N-terminus of GHRH(1-44), producing an analog that resists DPP-4 cleavage while retaining native receptor-binding geometry. It is one of the most extensively characterised long-acting GHRH analogs in published clinical research.
Published reference daily dose
| Reference daily dose | Published context |
|---|---|
| 2 mg | Adult research populations |
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
